Switzerland Giorgio Calderari, the chairman of Farma Industria Ticino, the association of chemical and pharmaceutical industries in the Swiss canton of Ticino, explains how a region with a population of 350,000 has managed to create a turnover of over two billion dollars, excelling as an innovative hub. Furthermore, he analyzes the…
China 2019 was a landmark year for the Chinese healthcare industry.* Since the publication of the ‘Healthy China 2030’ blueprint in 2016 by the Chinese government, the entire sector has been virtually turned upside down. Against the warm backdrop of regulatory support, a series of policy changes were unveiled in the…
China Hans Schmid, chairman; and Enrico Magnani, GM, of global cancer supportive care leader Helsinn Pharmaceuticals’ operations in China, share the Swiss company’s strategy in China, having entered in 2012; the milestone of launching their first product in China in November 2018 for chemotherapy-induced nausea and vomiting (CINV); the importance they…
Switzerland In view of the manifold hurdles encountered when attempting to raise capital, Switzerland’s medium capitalized entities and SMEs have grown adept at punching well above their weight. After the giants, Roche and Novartis, some of the larger companies in the Swiss pharma sector like Ferring and IBSA are privately held,…
Switzerland Helsinn is a leader in cancer supportive care, and Vice Chairman and CEO Riccardo Braglia enthusiastically discusses the Group’s entrance into the field of oncology therapeutics and the launch of the new Helsinn Investment Fund. Helsinn Advanced Synthesis in Biasca is a very advanced site capable of synthesizing high…
See our Cookie Privacy Policy Here